Why the study?
Does sulfinpyrazone reduce cardiac mortality in patients with a recent myocardial infarction?
Population
1475 patients with a recent documented myocardial infarction (entered 25 to 35 days after MI)
Comparison
Sulfinpyrazone 200 mg four times a day vs Placebo
Design
RCT, randomized, double-blind
Follow-up
average of 8.4 months
Loading...
Supports sulfinpyrazone post-MI; confirms cardiac mortality benefit in secondary prevention.
Does sulfinpyrazone reduce cardiac mortality in patients with a recent myocardial infarction?
Sulfinpyrazone significantly reduces cardiac mortality and sudden cardiac death during the first year after a recent myocardial infarction.
A 1978 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: